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Abstract
Background: Diabetic cardiomyopathy (DCM) is an increasingly recognized cause of chronic heart failure amongst diabetic
patients. Both increased reactive oxygen species (ROS) generation and impaired ROS scavenging have been implicated in
the pathogenesis of hyperglycemia-induced left ventricular dysfunction, cardiac fibrosis, apoptosis and hypertrophy. We
hypothesized that 39,49-dihydroxyflavonol (DiOHF), a small highly lipid soluble synthetic flavonol, may prevent DCM by
scavenging ROS, thus preventing ROS-induced cardiac damage.
Methodology/Principal Findings: Six week old homozygous Ren-2 rats were randomized to receive either streptozotocin or
citrate buffer, then further randomized to receive either DiOHF (1 mg/kg/day) by oral gavage or vehicle for six weeks.
Cardiac function was assessed via echocardiography and left ventricular cardiac catheterization before the animals were
sacrificed and hearts removed for histological and molecular analyses. Diabetic Ren-2 rats showed evidence of diastolic
dysfunction with prolonged deceleration time, reduced E/A ratio, and increased slope of end-diastolic pressure volume
relationship (EDPVR) in association with marked interstitial fibrosis and oxidative stress (all P,0.05 vs control Ren-2).
Treatment with DiOHF prevented the development of diastolic dysfunction and was associated with reduced oxidative
stress and interstitial fibrosis (all P,0.05 vs untreated diabetic Ren-2 rats). In contrast, few changes were seen in non-
diabetic treated animals compared to untreated counterparts.
Conclusions: Inhibition of ROS production and action by DiOHF improved diastolic function and reduced myocyte
hypertrophy as well as collagen deposition. These findings suggest the potential clinical utility of antioxidative compounds
such as flavonols in the prevention of diabetes-associated cardiac dysfunction.
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Introduction
The association between diabetes and cardiovascular disease is
beyond dispute, with diabetes being an independent risk factor for the
development of cardiovascular complications, accounting for 80% of
deaths among diabetic patients [1,2,3]. However the mechanisms
underlying the development of chronic heart failure (CHF) in diabetic
patients remain uncertain. A large body of evidence demonstrates
that diabetic cardiomyopathy (DCM) exists, independent of
hypertension and underlying coronary artery disease [4,5]. DCM is
characterized particularly by fibrosis and hypertrophy in the left
ventricle (LV) of the heart manifested as abnormal LV diastolic
function preceding LV systolic dysfunction [3,6,7].
While the mechanisms underlying these pathological changes
are not well understood, reactive oxygen species (ROS) have been
identified as likely mediators in the pathophysiology of diabetic
cardiovascular complications [8]. During the progression of DCM,
depletion of endogenous antioxidant reserves and hyperglycemia-
induced ROS generation causes a state of oxidative stress [9].
Hyperglycemia-induced overproduction of superoxide by the
mitochondrial electron-transport chain seems crucial to the
activation of various metabolic pathways implicated in diabetic
subjects. Superoxide overproduction is accompanied by increased
nitric oxide generation favouring the formation of the reactive
oxidant peroxynitrite which induces damage to biomacromole-
cules i.e. lipid peroxidation and protein oxidation and nitration
[10,11]. Also, activation of ROS-generating NADPH oxidase
isoforms in the heart by various stimuli during hyperglycemia
including angiotensin II (Ang II), endothelin-1 (ET-1), cytokines
and growth factors, appears to be important in redox-sensitive
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signalling leading to the accumulation of extracellular matrix
(ECM) proteins, interstitial and perivascular fibrosis and myocyte
hypertrophy causing LV remodelling [12,13,14,15].
Current evidence-based therapies for the treatment of diabetes
and cardiac disease, including ACE inhibitors, angiotensin
receptor blockers (ARB), and statins have some intracellular
antioxidant activity [16]. Despite the abovementioned treatments
and intensive glucose or blood pressure control, CHF remains a
major public health burden with the need for new therapeutic
strategies. Flavonols are plant-derived polyphenolic compounds
that have been recognized to not only scavenge intracellular and
extracellular ROS but to also inhibit enzymes responsible for the
production of superoxide anions including xanthine oxidase,
NADPH oxidase, cyclooxygenase, lipoxygenase, and protein
kinase C [17,18]. Recently, DiOHF (39,49-dihydroxyflavonol), a
small highly lipid soluble synthetic flavonol, has been demonstrat-
ed to attenuate myocardial ischemia/reperfusion injury, associated
with its antioxidant activity [19,20]. However, the antioxidant
actions of orally administered DiOHF have yet to be tested in the
setting of hyperglycemia-induced DCM.
Accordingly, the present study aimed to examine the effects of
DiOHF on cardiac function and structure in experimental DCM.
The study was undertaken in the streptozotocin-induced trans-
genic m(Ren-2)27 rat, a hemodynamically validated model of
diabetes-induced diastolic heart failure, which has been shown to
develop structural and functional changes similar to that observed
in human DCM [21,22]. We demonstrated that DiOHF
effectively reduced cardiac oxidative stress and was cardioprotec-
tive against cardiac dysfunction that develops as a consequence of
diabetes.
Materials and Methods
Ethics statement
Experimental procedures were approved by the St Vincent’s
Hospital Animal Ethics Committee, Melbourne, Australia in
accordance with the National Health and Medical Research
Council of Australia’s Code of the Care and Use of Animals for
scientific purposes: Ethics Approval ID. 063/03 (PC2 certificate
number. 1480/2003, Permit number. SPPL120).
Animals and procedures
Six week old male homozygous transgenic m(Ren-2)27 rats (St.
Vincent’s Hospital Animal Resource Centre, Melbourne, Victoria,
Australia) were randomized to receive either 55 mg/kg of
streptozotocin (STZ; Sigma, St Louis, MO, USA) diluted in
0.1 mol/L citrate buffer pH 4.5 (diabetic) to induce experimental
type 1 diabetes or citrate buffer alone (non-diabetic control) by tail
vein injection following overnight fasting. Diabetic and control rats
(n = 10) were further randomized to receive either an orally active
synthetic antioxidant, DiOHF (39,49-dihydroxyflavonol; Indofine
Chemical Co., USA) at 1 mg/kg or vehicle (1% carboxy methyl
cellulose solution; CMC) by daily gavage for six weeks post STZ.
DiOHF was a gift from NeuProtect Pty Ltd, Melbourne VIC.
Animals were housed in a stable environment maintained at
2161uC (12 hour light/dark cycle commencing at 6 am). Animals
had free access to standard rat chow (GR2 Clark-King and Co,
Gladesville, NSW, Australia) and drinking water.
Each week, rats were weighed and their blood glucose levels were
measured (Accucheck Advantage II Blood Glucose Monitor, Roche
Diagnostics, USA). Only STZ-treated animals with blood glucose
greater than 15 mmol/L were considered diabetic. Prior to the
induction of diabetes and every three weeks post randomization,
systolic blood pressure (SBP) was assessed in preheated conscious
rats by tail cuff plethysmography using a non-invasive blood
pressure controller and Powerlab system (AD Instruments Pty Ltd,
NSW, Australia) [23,24]. Diabetic animals received 2–4 units of
isophane insulin (Humulin NPH; Eli Lilly and Co., NSW, Australia)
intraperitoneally 3 times per week to maintain blood glucose levels,
promote weight gain and reduce mortality.
At the end of the experimental period, animals were
anaesthetized (pentobarbitone sodium 30 mg/kg body weight
i.p.; Virbac, Peakhurst, NSW, Australia). The abdomen, neck, and
chest were shaved, and echocardiography performed followed by
in vivo left ventricular pressure-volume loop acquisition.
Echocardiography
Detailed two dimensional and Doppler echocardiography were
performed to assess systolic and diastolic function using a Vivid 7
Dimension (GE Vingmed, Horten, Norway) echocardiograph with
a 10 MHz phased array probe, as previously published [21].
Animals underwent echocardiographic interrogation in the left
recumbent position, after being anaesthetized using the protocol
above. All data were acquired and analyzed by a single blinded
observer using EchoPAC (GE Vingmed) offline processing.
Cardiac catheterization
Cardiac catheterization was performed as previously published
[21]. Post echocardiography, animals were placed on a warming
pad (37uC), intubated using a 14 gauge catheter, and ventilated
using positive pressure with a tidal volume of 8 to 10% body weight
at 70 breaths/min using room air. The right internal carotid artery
was identified, ligated, and a 2F miniaturized combined conduc-
tance catheter-micromanometer (Model SPR-838 Millar instru-
ments, Houston, TX) was inserted to obtain aortic blood pressure,
then advanced into the LV until stable PV loops were obtained.
Data were acquired under steady state conditions and during
preload reduction. Using the pressure conductance data, a range of
functional parameters was then calculated (Millar analysis software
PVAN 3.4). These included end diastolic pressure (EDP), end
systolic pressure (ESP), the time constant of the isovolumic-pressure
decline (Tau, t Weiss), the slope of end diastolic pressure volume
relationship (EDPVR), and the slope of the preload recruitable
stroke work relationship (PRSW), defined as the relationship
between stroke work (SW) and end diastolic volume (EDV) [21].
The active and passive phases of diastole were resolved by the
assessment of Tau and EDPVR, respectively.
Tissue collection
Animals were euthanized with a further dose of anaesthetic
(pentobarbitone sodium 60 mg/kg of body weight i.p.; Virbac,
Peakhurst, NSW, Australia) and their hearts and lungs excised. The
whole heart and lung were blotted dry and weighed. The heart was
then dissected into atria, right ventricle and left ventricle, inclusive
of the interventricular septum, and weighed separately. The apex
was removed, bisected and snap frozen in280uC liquid nitrogen for
chemiluminescence. The top portion of the LV was fixed in 10%
neutral buffered formalin overnight for subsequent processing and
the mid portion was embedded in Tissue-TekH OCT compound
(Sakura Finetek USA, Inc., Torrance, CA, USA) and stored in a
280uC freezer. The formalin-fixed LV sections were paraffin-
embedded and sectioned to 4 mm thick using a rotary microtome
(Leica Microsystems GmbH Wetzlar, Germany).
Histopathology and immunohistochemistry
Changes in cardiac structure were assessed in a masked protocol
in at least 10 randomly selected tissue sections from each group
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studied. Sections were stained with picrosirius red to demonstrate
collagenous matrix and fibrillar collagen types I and III were assessed
using specific antibodies (anti-type I collagen 1:100: Southern
Biotechnology Associates Inc., Birmingham, AL, USA; anti-type III
collagen antibody: Biogenex, San Ramon, CA, USA). Indication of
oxidative damage within the myocardium was assessed using anti-
nitrotyrosine 1:40 (Upstate, NY, USA). In brief, 4 mm LV sections
were dewaxed in histolene, rehydrated in graded ethanol, and
immersed in distilled water. Each LV section was incubated in
100 mL of picrosirius red (Merck Pty Ltd, Kilsyth, Victoria, Australia)
solution for 1 hour at room temperature to aid visualization of
collagenous matrix. Sections were then briefly rinsed in 2 changes of
acidified water (1% acetic acid), dehydrated in 26100% ethanol for
3 minutes each and 26 histolene for 2 minutes each, and cover-
slipped with DPX mounting media. Immunohistochemistry was
performed on 4 mm sections, as previously described [21].
Measurement of cardiomyocyte hypertrophy
The extent of cardiac myocyte hypertrophy, as measured by
cross sectional area (CSA), was determined on haemotoxylin-eosin
stained sections as previously published [21]. In brief, only
myofibers with intact cellular membranes from field with circular
capillary profiles and myofiber shapes were assessed and the
circumferences of 20–30 cells per LV were traced and digitized to
calculate mean CSA.
Quantification of histological parameters
The accumulation of matrix (picrosirius red) and the extent of
immunostaining of collagen I, collagen III, and 3-nitrotyrosine were
quantified using computer-assisted image analysis software, as
previously described [21]. Sections were scanned and digitized using
Aperio ScanScope Console v.8.0.0.1058 (Aperio Technologies, Inc).
Ten random non-overlapping fields from each section around the
subendocardial region were captured using Aperio ImageScope
v.8.0.39.1059 (Aperio Technologies, Inc) or Axioimager.A1 micro-
scope attached to an AxioCam MRe5 digital camera (Carl Zeiss
AxioVision, Germany) at 6230 magnification. Images were then
exported and loaded onto a Pentium D Dell computer. An area of
red on picrosirius red-stained (for matrix) or brown on immuno-
stained sections (for collagen I and collagen III) were highlighted
using a selective colour tool. Calculation of proportional area
stained red or brown was determined using image analysis software
AIS (Analytic Imaging Station version 6.0, Imaging Research Inc.,
Ontario, Canada) or AxioVs40LE (AxioVision version 4.5.0.0).
NADPH oxidase activity
NADPH oxidase-dependent superoxide production in LV tissues
was measured using lucigenin-enhanced chemiluminescence (LEC)
as previously described [25]. Equal size of LV tissues were
homogenized using glass homogenizer in the buffer containing
250 mM sucrose and 10 mM HEPES with protease inhibitors.
Lysate was collected by centrifugation at 12,000 rpm for 10 mins at
4uC. Protein was quantitated and equal amount of lysate was
transferred into a 96-well OptiPlate (Packard BioScience, Australia)
with 200 ml Krebs-HEPES buffer in each well. 5 mM lucigenin and
100 mM NADPH were added into each well and the chemilumi-
nescence was detected using a POLARstar OPTIMA plate reader
(BMG Labtech, Offenburg, Germany). All the chemiluminescence
data were normalised to protein concentration.
Real-time quantitative polymerase chain reaction (PCR)
Real-time quantitative PCR was used to assess transcript levels
of thioredoxin-interacting protein (TXNIP, NM_006472), Cu/Zn
superoxide dismutase (SOD1, NM_017050), and glutathione
peroxidase (Gpx1, NM_030826). A 20–25 mL of real-time PCR
reaction included Brilliant SYBR Green QRT-PCR Master Mix
as per manufacturer’s instructions (Stratagene, USA). Real-time
quantitations were performed using ABI Prism 7000 Sequence
Detection System (Applied Biosystems, CA, USA) according to
manufacturer’s instructions. The fluorescence threshold value was
calculated and the calculation of relative change in mRNA was
performed using the delta-delta CT method, with normalization
for the housekeeping gene 18s. Nucleotide sequences of primers
were as follows:
TXNIP (forward) 59-AGGATTCTGTGAAGGTGATG-39
TXNIP (reverse) 59-TCTGACTGAGGACAGCTTCT-39
SOD1 (forward) 59-CGGTGCAGGGCGTCATTCACTT-39
SOD1 (reverse) 59-CCGCTGGACCGCCATGTTTCTT-39
Gpx1 (forward) 59-GGTGCTGGGCTCTGACTGCG-39
Gpx1 (reverse) 59-GCGCGCGGAGAAGGCATACA-39
18S (forward) 59-TCGAGGCCCTGTAATTGGAA-39
18S (reverse) 59-CCCTCCAATGGATCCTCGTT-39
33P in situ hybridization
Synthesis of riboprobes and in situ hybridization were
performed as previously described [25,26]. Briefly, 33P-labelled
antisense RNA probe for Txnip was generated by in vitro
transcription (Promega, WI, USA) from linearized templates.
Primers were designed using Oligo 6 primer design software
(Molecular Biology Insight, CO, USA). Two rat Txnip probes
were generated by RT-PCR, using rat kidney cDNA as template,
to span the regions 1481–2004 (540 bp) and 2008–2384 (377 bp)
of the rat Txnip sequence (NM_001008767). Purified riboprobe
length was adjusted to approximately 150 bases by alkaline
hydrolysis. In situ hybridization was performed on 4 mm thick
sections of formaldehyde-fixed, paraffin-embedded LV tissue.
Briefly, tissue sections were dewaxed in histolene, rehydrated in
graded ethanol, and microwaved in 10 mM citrate buffer pH 6.0
on medium-high (600 to 700 W) for 5 min. Sections were washed
in 0.1 M sodium phosphate buffer pH 7.2, fixed in 4%
paraformaldehyde for 10 min, and washed again in phosphate
buffer and milliQ water. After equilibration in P buffer (50 mM
Tris-HCl pH 7.2 and 5 mM EDTA pH 8.0), slides were
incubated with 125 mg/ml Pronase E (Sigma) in P buffer
pH 7.2, refixed in 4% paraformaldehyde for 10 min, rinsed in
milliQ water, dehydrated in 70% ethanol, and air dried.
Hybridization of the riboprobe to the pretreated tissue was
performed overnight at 60uC in 50% formamide-humidified
chambers. Sense probes were used on an additional set of tissue
sections as controls for nonspecific binding. After hybridization,
slides were washed, incubated with RNase A, dehydrated in
graded ethanol, air dried, and exposed to Kodak Biomax MR
autoradiographic film (Kodak, Rochester, NY) for 3 days.
Quantitative autoradiography
Densitometry of autoradiographic images obtained by in situ
hybridization was performed by computer-assisted image analysis
using Micro Computing Imaging Device (MCID; Imaging
Research, Ontario, Canada) as previously described [25]. In
brief, in situ autoradiographic images were placed on a uniformly
illuminating fluorescent light box (Northern Light Precision
Luminator model C60) and captured using a video camera (Dage
MTI CCD72) connected to an IBM AT computer with a
5126512 pixel array imaging board with 256 grey levels. After
calibration by construction of a curve of optical density versus
radioactivity density using Amersham 14C microscale autoradiog-
raphy standard, which were co-exposed with the hybridized
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sections, quantification of digitalized autoradiographic images was
performed with the MCID software and expressed as nCi/g.
Western blot
Western blots were performed as previously described [27].
Protein concentration of heart tissue homogenates were deter-
mined using Bio-Rad Bradford Protein Assay (Bio-Rad, CA,
USA). Samples with equal concentration of protein were subjected
to SDS-PAGE and western blot analysis with rabbit polyclonal
Txnip antibody overnight at 4uC (1:1000: Invitrogen, CA, USA).
Following incubation with anti-rabbit secondary antibody (1:2500:
Dako, Golstrup, Denmark) for 1 hour at room temperature,
proteins were detected by ECL detection system. The membranes
were reprobed with pan-actin (1:500: Neomarkers, CA, USA),
which served as loading control. The bands corresponding to
Txnip (50 kDa) and pan-actin (42 kDa) were quantitated by
densitometry using Quantity One Software (Bio-Rad, CA, USA)
and expressed as the ratio of the loading control. At least six
samples were analysed from each group in four separate gels.
Statistical analyses
Data were expressed as mean 6 standard error of mean (SE)
unless otherwise stated. Differences between groups were deter-
mined by one-way analysis of variance (ANOVA) with Fisher
PLSD post hoc comparison using Statview II + Graphics package
(Abacus Concepts, Berkeley, CA). A value of P,0.05 was
considered as statistically significant.
Results
Animal characteristics of homozygous Ren-2 rats with or
without diabetes for 6 weeks
All rats were hypertensive with elevated systolic blood pressure.
Blood glucose was elevated to a similar extent in diabetic animals.
Body weight and heart weight, indexed to body weight (HW:BW)
were reduced in diabetic rats. DiOHF treatment did not
significantly alter BGL, SBP, BW or HW:BW in either control
or diabetic animals (Table 1).
DiOHF attenuated left ventricular diastolic dysfunction in
diabetic Ren-2 rats as assessed by cardiac catheterization
and echocardiography
Chamber compliance, a measure of diastolic function was
significantly reduced in diabetic rats (P,0.05) when compared to
control rats (Table 2b, Fig. 1). Chamber compliance is inversely
proportional to the slope of end-diastolic pressure volume
relationship (EDPVR). Treatment of diabetic rats with DiOHF
improved chamber compliance to levels comparable to control rats
(P,0.05; Table 2b, Fig. 1). Active relaxation, as measured by Tau
t, was significantly prolonged in diabetic compared to control rats.
Table 1. Animal characteristics of control and diabetic rats treated with vehicle or DiOHF.
Control Control + DiOHF Diabetic Diabetic + DiOHF
N 12 7 10 11
BGL (mmol/L) 32.8 6 0.1 31.2 6 0.6
SBP (mmHg) 245 6 6.2 236.6 6 12.2 235.8 6 20.3 236.7 6 19.6
BW (g) 318.00 6 12.12 301.14 6 13.35 224.67 6 8.13* 217.82 6 7.01*
HW:BW 0.52 6 0.014 0.53 6 0.061 0.41 6 0.017* 0.41 6 0.008*
Lung:BW 0.51 6 0.025 0.49 6 0.022 0.58 6 0.033 0.61 6 0.033
Values are Mean 6 SE; BGL, Blood glucose level; SBP, Systolic blood pressure; BW, Body weight, HW, Heart weight.
*P,0.05 vs control (non-diabetic) rats.
doi:10.1371/journal.pone.0022777.t001
Table 2. Steady state and load insensitive parameters of cardiac contraction and relaxation.
Control Control + DiOHF Diabetic Diabetic + DiOHF
A
N 9 5 8 10
HR (bpm) 295 6 15 278 6 30 246 6 12* 245 6 8
EDV (mL) 207.42 6 16.98 203.94 6 30.35 260.38 6 31.99 225.68 6 18.63
EDP (mmHg) 4.62 6 0.51 5.20 6 0.55 10.05 6 0.91* 5.94 6 0.57{
B
dP/dt max (mmHg / sec) 5394 6 827 4115 6 632 5199 6 872 5207 6337
Tau t (msec) Weiss 14.2 6 0.8 14.5 6 1.0 17.0 6 0.8* 14.7 6 0.6{
EDPVR (slope-mmHg/mL) 0.026 6 0.004 0.030 6 0.005 0.060 6 0.011* 0.027 6 0.002{
PRSW (slope-mmHg) 106 6 15 123 6 28 44 6 7* 71 6 8
Values are Mean6 SE; A: HR, Heart rate; EDV, End-diastolic volume; EDP, End-diastolic pressure; B: dP/dt max, the maximal rate of pressure change; Tau, time constant of
pressure decay; PRSW, slope of preload recruitable stroke work relationship; EDPVR, slope of end-diastolic pressure volume relationship.
*P,0.05 vs control (non-diabetic) rats;
{P,0.05 vs diabetic rats.
doi:10.1371/journal.pone.0022777.t002
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Figure 1. Representative pressure volume (PV) loops during preload reduction. Note the steeper slope of EDPVR (green line) and
rightward shift in the diabetic group (C) compared to control (A). An increase in the slope of EDPVR indicated decreased chamber compliance as seen
in the diabetic animals which was reduced with DiOHF treatment (D). *P,0.05 vs control (non-diabetic) rats; {P,0.05 vs diabetic rats.
doi:10.1371/journal.pone.0022777.g001
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DiOHF treatment significantly attenuated the increase in Tau t in
diabetic animals (P,0.05; Table 2b).
Diastolic function, assessed using Doppler echocardiographic
examination, showed a significant reduction in E to A ratio in
diabetic animals when compared to control rats (P,0.05) with a
trend to improvement following DiOHF treatment (Table 3,
Fig. 2). Diabetic rats demonstrated impaired relaxation with
prolonged deceleration time (DT) of early (E) diastolic filling
compared to control rats (P,0.05), which was significantly
improved with DiOHF treatment (P,0.05; Table 3). There
were no significant differences in any cardiac parameters
measured in control rats when compared to control rats treated
with DiOHF.
Heart rate was significantly reduced in diabetic rats when
compared to control rats (P,0.05). DiOHF treatment did not
significantly alter heart rate in either diabetic or control animals
(Table 2a). End-diastolic pressure (EDP) was significantly elevated
in diabetic compared to control rats (P,0.05) and was attenuated
by DiOHF in diabetic rats.
DiOHF ameliorated myocardial fibrosis and cellular
hypertrophy in diabetic Ren-2 rats
Diabetes was associated with a significant increase in myocar-
dial fibrosis as evidenced by greater proportional area of interstitial
collagen I and III immunostaining (Fig. 3 and 4) and extracellular
matrix deposition (data not shown). Diabetic rats also displayed
cellular hypertrophy with increased cardiomyocyte cross-sectional
area when compared with control rats (P,0.05; Fig. 5). DiOHF
treatment significantly attenuated myocardial fibrosis and cellular
hypertrophy (P,0.05 versus diabetic).
DiOHF attenuated cardiac oxidative stress in diabetic
Ren-2 rats, independent of changes in the gene
expression of intracellular antioxidant enzymes
The presence of diabetes resulted in significant induction of
intracellular oxidative stress as measured by increased tissue
localisation of 3-nitrotyrosine and NADPH oxidase-dependent
superoxide production (P,0.05 versus control), which were
significantly attenuated by DiOHF in diabetic rats (P,0.05;
Fig. 6). Similarly, Txnip mRNA and protein expression levels were
significantly increased in diabetic compared to control rats
(P,0.05 versus control) and were attenuated by DiOHF treatment
(Fig. 8 and 9). No significant differences were observed in the
control rats when compared to control-treated rats.
Diabetic animals demonstrated a marked increase in the gene
expression of intracellular antioxidant enzymes such as superoxide
dismutase (SOD1) and glutathione peroxidase (Gpx1) when
compared to control rats (Fig. 7). SOD1 and Gpx1 mRNA levels
were not changed by DIOHF treatment in diabetic rats.
Discussion
Clinically, DCM is characterized by early abnormalities in LV
diastolic function that ultimately lead to chronic heart failure
with subtle or no changes in LV systolic function [28]. The most
prominent cardiac remodelling event associated with these
functional alterations is myocardial fibrosis with the accumula-
tion of extracellular matrix components including collagen types
I and III [28,29]. The present study demonstrates that
suppression of oxidative stress with DiOHF, a broad spectrum
antioxidant, in an experimental model of diastolic heart failure
due to diabetes, led to improved chamber compliance, reduced
myocyte hypertrophy and collagen deposition. To our knowl-
edge, this is the first study showing that oral antioxidant therapy
with DiOHF prevents hyperglycemia-induced oxidative stress-
mediated myocardial injury and may represent a novel therapy
to explore clinically.
The pathogenesis of LV dysfunction in diabetic hearts has not
been fully elucidated. The correlation between hyperglycemia and
oxidative stress demonstrated in clinical and experimental studies
may be due to the upregulation of local renin-angiotensin systems
(RAS) [30]. Here, we have demonstrated that DiOHF treatment
did not significantly alter cardiac function and structure in non-
diabetic Ren-2 rats in the presence of an enhanced local RAS
alone. However, induction of diabetes in Ren-2 rats resulted in
marked deterioration of cardiac pathology, which was significantly
attenuated by DiOHF treatment. The sensitization of local RAS
by hyperglycemia has been associated with upregulation of the
AT1 receptor and increase in ROS via stimulation of NADPH
oxidase activity [30,31]. In the present study, localization of 3-
nitrotyrosine, a biomarker of oxidative stress was markedly
reduced in the myocardium of diabetic Ren-2 rats treated with
DiOHF, in conjunction with a reduction in interstitial collagenous
matrix deposition. We also demonstrated that DiOHF led to a
reduction in NADPH oxidase-dependent superoxide production
in the LV sections from diabetic Ren-2 rats. These results are in
accord with Wang and colleagues [20], who established that the
antioxidant actions of DiOHF were responsible for the attenuation
of myocardial ischemia-reperfusion injury.
Table 3. Echocardiographic parameters in control and diabetic rats, treated with or without DiOHF for 6 weeks.
Control Control + DiOHF Diabetic Diabetic + DiOHF
FAC (%) 66.99 6 2.30 71.62 6 3.90 71.07 6 2.78 74.42 6 3.26
LVID d 0.58 6 0.02 0.56 6 0.03 0.64 6 0.02* 0.58 6 0.02
LVID s 0.27 6 0.01 0.22 6 0.02 0.26 6 0.02 0.20 6 0.02{
FS % (M mode) 53.38 6 1.75 61.57 6 3.08 59.89 6 2.63 66.00 6 2.98
EF (%) 80.46 6 1.41 79.06 6 2.68 75.79 6 0.71 81.69 6 1.42
Dec T (ms) 36.75 6 3.90 37.33 6 4.63 45.29 6 2.06* 31.83 6 1.19{
E/A ratio 1.85 6 0.29 1.53 6 0.03 1.41 6 0.08* 1.72 6 0.12
Values are Mean 6 SE; FAC, Fractional Area Change; LVID d, Left Ventricular Internal end Diastolic dimension; LVID s, Left Ventricular Internal end Systolic dimension; EF,
Ejection Fraction; FS, Fractional Shortening; Dec T, Deceleration time.
*P,0.05 vs control (non-diabetic) rats;
{P,0.05 vs diabetic rats.
doi:10.1371/journal.pone.0022777.t003
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The exact mechanisms leading to the observed structural and
functional improvements in DCM with DiOHF therapy remain
speculative. Flavonols have long been recognized for their ability
to scavenge superoxide radicals and to inhibit enzymes responsible
for the production of oxygen radicals [32,33]. DiOHF may exert
pleiotropic effects in the diabetic Ren-2 hearts not only through
increasing ROS scavenging or decreasing NADPH oxidase-
dependent superoxide production but also perhaps by restoring
the function of intracellular enzymatic or non-enzymatic antiox-
idants. The thioredoxin system, one of the major intracellular
antioxidant defense mechanisms, prevents oxidative stress by
removing oxygen radical intermediates. However, the antioxida-
tive function of thioredoxin is inhibited when thioredoxin
interacting protein (Txnip) binds to the catalytic site of the
reduced form of thioredoxin [34,35]. Txnip has been shown to be
increased in the hearts of streptozotocin-induced diabetic mice,
suggesting that diabetes-induced alterations in redox balance may
contribute to the pathological processes in DCM [36]. Consistent
with previous findings in diabetic Ren-2 kidneys, Txnip mRNA
and protein expression levels were elevated in the hearts of
diabetic Ren-2 animals [26,37]. We further demonstrated that
Txnip overexpression in the diabetic Ren-2 hearts was prevented
when treated with DiOHF, possibly leading to the restoration of
thioredoxin activity [26]. In addition, the enhanced gene
expression of Cu/Zn-superoxide dismutase and glutathione
peroxidase in the presence of diabetes suggests that there could
be compensatory mechanisms to protect against oxidative stress
[38,39]. The expression of these antioxidant enzymes remained
higher in diabetic-treated than in control-untreated Ren-2
animals, despite notable restoration of cardiac redox balance.
Although we were unable to evaluate the functional integrity of
these antioxidant enzymes, we cannot exclude the possibility that
these enzymes may have reduced or impaired function as a result
of post-translational modifications, such as glycation, and
nitration, by different reactive intermediates commonly present
in the diabetic milieu [40,41,42,43].
Current therapies available for the prevention of CHF in
diabetic patients target glycemic and blood pressure control,
predominantly through blockade of the RAS [3,44]. For instance,
chronic AT1 receptor blockade by candesartan in type 2 diabetic
patients reduced myocardial fibrosis correlated with improved
diastolic function [45]. However, large-scale clinical trials, such as
I-PRESERVE (Irbesartan in HF with Preserved Systolic Function)
and CHARM-Preserved (Candesartan in Heart Failure to Affect
Reduction in Morbidity and Mortality), showed moderate or no
improvement in cardiovascular mortality and morbidity among
patients with heart failure and preserved LV ejection fraction (HF-
PEF) [46,47]. Retrospective cohort studies from these clinical trials
demonstrated that diabetes was present in approximately 28% of
HF-PEF patients and was identified as an independent predictor of
cardiovascular mortality and HF hospitalization [48,49]. These
treatments are to a certain extent effective at delaying the onset of
CHF in patients presented with systolic dysfunction (LVEF,40%)
but not much is known about the impact of these therapies on the
Figure 2. Representative apical view pulsed wave Doppler studies. In control rats (A) ‘‘normal’’ left ventricular (LV) filling pattern were
observed, whereas diabetic rats (B) had reduced LV function. These changes were distinguished by delayed ventricular relaxation, characterized by
reduction in the E wave and an increase in the late atrial A wave and prolongation of the deceleration time. Treatment with DiOHF showed
improvement in LV function of diabetic rats (C).
doi:10.1371/journal.pone.0022777.g002
Figure 3. Immumohistochemistry staining for collagen type I. (A) Representative images. Brown region represents positive immunostaining
for collagen type I which was substantially increased in diabetic rats and reduced by DiOHF treatment. The amount of collagen type I was found to be
similar in control and control-treated rats. Collagen type I interstitial accumulation as assessed by percentage proportional area showing positive
immunostaining in control and diabetic rats treated with or without DiOHF (B). Data expressed as mean 6 SE. *P,0.05 vs control (non-diabetic) rats;
{P,0.05 vs diabetic rats. Original magnification6200.
doi:10.1371/journal.pone.0022777.g003
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various stages of diastolic dysfunction. This further highlights the
absence of therapeutic interventions for diastolic heart failure
among diabetic patients [50]. Here, diabetic Ren-2 rats that were
administered a therapeutic dose of DiOHF demonstrated up to
55% improvement in chamber compliance when compared to
untreated diabetic Ren-2 rats. The passive diastolic properties of
Figure 4. Immunohistochemistry staining for collagen type III. (A) Representative images. Brown region represents positive immunostaining
for collagen type III which was substantially increased in diabetic rats and reduced by DiOHF treatment. The amount of collagen type III was found to
be similar in control and control-treated rats. Collagen type III interstitial accumulation as assessed by proportional area on sections showing positive
immunostaining in control and diabetic rats treated with or without DiOHF (B). Data expressed as mean6 SE. Data expressed as mean6 SE. *P,0.05
vs control (non-diabetic) rats; {P,0.05 vs diabetic rats. Original magnification6200.
doi:10.1371/journal.pone.0022777.g004
Figure 5. Representative images for myocyte hypertrophy. (A) Diabetic rats demonstrated myocyte hypertrophy as evidenced by increased
cross sectional area when compared with control rats. Treatment with DiOHF reduced cross sectional area in diabetic rats but had no effect on
control rats. (B) Quantitative data for myocyte cross sectional area. *P,0.05 vs control (non-diabetic) rats; {P,0.05 vs diabetic rats. Original
magnification6200.
doi:10.1371/journal.pone.0022777.g005
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the LV were normalized to the level observed in control Ren-2
group. However, whether DiOHF antioxidant might provide
additional therapeutic benefits when added to angiotensin-
converting enzyme inhibition or angiotensin receptor blockade
have yet to be assessed.
Echocardiography and invasive pressure-volume (PV) loops
analysis were performed to investigate the active and passive
properties of the LV during diastole, along with assessment of
systolic performance. During early diastolic dysfunction, impaired
LV relaxation and compliance is denoted by reduced magnitude
of E wave, compensated by increased atrial contraction, resulting
in reduced E:A ratio, as observed in diabetic Ren-2 animals
[28,51]. Also, impaired relaxation with prolonged deceleration
time (DT) was observed in diabetic Ren-2 animals. However,
interpretation of intrinsic diastolic properties using echocardiog-
raphy is limited due to the preload dependence [28,52] and
recently highlighted heart rate dependence [53] of the Doppler LV
filling parameters. Consequently, load-insensitive measurements of
chamber compliance were determined by examining end-diastolic
pressure-volume relationship (EDPVR) over varying loading
conditions [54]. We demonstrated that the marked reduction in
chamber compliance in Ren-2 diabetic animals was attenuated by
treatment with DiOHF antioxidant at the time point assessed. The
rate of relaxation, measured by time constant of relaxation (Tau)
Figure 6. Measurements of oxidative stress. Representative images for the localization of 3-nitrotyrosine in LV tissues, as assessed by the
proportional area of positive immunostaining in control and diabetic rats treated with or without DiOHF (A). The marked increase in positive
immunostaining (brown region) for 3-nitrotyrosine in diabetic rats was reduced by DiOHF treatment. The amount of 3-nitrotyrosine was found to be
comparable in control and control-treated Ren-2 rats (B). Original magnification6200. (C) NADPH-activated superoxide production in LV tissues as
measured by lucigenin-enhanced chemiluminescence. Data expressed as mean6 SE. *P,0.05 vs control (non-diabetic) rats; {P,0.05 vs diabetic rats.
doi:10.1371/journal.pone.0022777.g006
Figure 7. Intracellular antioxidants mRNA gene expression. (A) Measurement of Cu/Zn-superoxide dismutase (SOD1) and (B) gluthathione
peroxidase (Gpx1) mRNA by real time RT-PCR, normalized to the housekeeping gene 18s. Diabetic rats demonstrated increased gene expression of
SOD1 and Gpx1, which were not affected by DiOHF. Data expressed as mean 6 SE. *P,0.001 vs control (non-diabetic) rats.
doi:10.1371/journal.pone.0022777.g007
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during the active phase of diastole, was also prolonged in Ren-2
diabetic animals.
These data are consistent with the manifestation of LV diastolic
dysfunction frequently found in diabetic patients without other
known cardiac defects, such as atherosclerosis or hypertension
[28,55]. Martos et al. [56] demonstrated that markers of collagen
turnover associated with active fibrotic processes were elevated in
patients diagnosed with more severe phases of diastolic dysfunc-
tion. Using non-invasive monitoring of myocardial fibrosis in
diabetic patients, the change in LV chamber compliance has been
correlated to regulation of collagen turnover [57]. In our study, the
diabetic Ren-2 rats treated with DiOHF demonstrated significant
reduction in cardiac myocyte hypertrophy and collagen types I
and III. These structural effects may have contributed to the
observed improvement in chamber compliance.
In contrast, load-dependent indices of systolic function exam-
ined by fractional shortening (FS) and fractional area change
(FAC) showed no significant differences among diabetic and
control Ren-2 animals. Similarly, the LV ejection fraction (EF) was
within the normal range (EF.60%) across all groups. The
assessment of systolic function by conventional echocardiography
is not only influenced by cardiac contractility but other factors
including loading conditions and heart rate [58]. In the present
study, the ‘gold standard’ invasive PV loops analysis of diabetic
Ren-2 rats showed a reduction in the slope of preload recruitable
stroke work relationship (PRSW), indicative of subtle differences in
cardiac contractility, that were not detected by echocardiography.
Further, DiOHF treatment tended to improve PRSW in diabetic
rats indicating improved systolic function. These findings are
consistent with clinical findings where diastolic dysfunction is often
accompanied by systolic dysfunction in diabetes.
The current study has established the potential clinical utility of
antioxidant therapy in preventing the development of diabetic
cardiomyopathy, despite persistent hypertension and hyperglyce-
mia. The early induction of therapy following onset of diabetes
may account for the vast improvement in functional parameters
measured in diabetic-treated Ren-2 animals. However, it remains
to be explored if the current therapy would continue to preserve
cardiac function in the presence of sustained severe hyperglycemia
among diabetic subjects. Hence, it would be of considerable
interest to examine the effect of DiOHF therapy on the
myocardium in the presence of diabetes at a later time point.
In conclusion, diabetic Ren-2 rats treated with DiOHF
demonstrated improved diastolic function with a trend towards
improved systolic function. DiOHF therapy reduced the accumu-
lation of extracellular matrix components, particularly collagen
types I and III, which are associated with myocardial fibrosis
observed in diabetic Ren-2 rats. These findings suggest that
DiOHF therapy is cardioprotective in diabetic Ren-2 rats, and
these data may have implications in the clinical setting with clinical
trials using similar antioxidants in the context of diastolic heart
failure has just begun (GRAPEVINE-HF, NCT01185067).
Figure 8. Txnip mRNA gene expression. (A) Representative autoradiographs from in situ hybridization of Txnip. The magnitude of gene
expression is indicated quantitatively as a pseudocolourized computer image (blue, nil; green, low; yellow, moderate; red, high). (B) Quantitation of
Txnip gene expression by quantitative autoradiography. (C) Measurement of Txnip mRNA by real time RT-PCR, normalized to the housekeeping gene
18s. Data expressed as mean 6 SE. *P,0.05 vs control (non-diabetic) rats; {P,0.05 vs diabetic rats.
doi:10.1371/journal.pone.0022777.g008
Figure 9. Txnip protein expression. (A) Representative western blot and (B) quantitation of Txnip normalized to loading control pan-actin. The
significant increase in Txnip protein in diabetic rats was moderately reduced by DiOHF treatment. Data expressed as mean 6 SE. *P,0.05 vs control
(non-diabetic) rats.
doi:10.1371/journal.pone.0022777.g009
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